| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K01737880 | CTRPv2 | pan-cancer | AAC | -0.16 | 0.3 |
| mRNA | PF-543 | CTRPv2 | pan-cancer | AAC | 0.036 | 0.3 |
| mRNA | selumetinib:navitoclax (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.035 | 0.3 |
| mRNA | B02 | CTRPv2 | pan-cancer | AAC | 0.035 | 0.3 |
| mRNA | NVP-231 | CTRPv2 | pan-cancer | AAC | -0.031 | 0.4 |
| mRNA | Compound 23 citrate | CTRPv2 | pan-cancer | AAC | 0.032 | 0.4 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | -0.034 | 0.4 |
| mRNA | PD 153035 | CTRPv2 | pan-cancer | AAC | -0.039 | 0.4 |
| mRNA | BRD-K11533227 | CTRPv2 | pan-cancer | AAC | 0.035 | 0.4 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | -0.035 | 0.4 |